a study for dosage of Andriol Testocaps in treatment of late-onset hypogonadism

differential dosage of Andriol Testocaps in treatment of Chinese patients with late-onset hypogonadism

Status

Withdrawn

Phases

Unknown

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12616000114448

Enrollment

Registered

2016-02-02

Start date

2016-02-12

Completion date

2016-12-01

Last updated

2020-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Overload dosage of Andriol Testocaps will not benefit the patients with LOH. In China, the patients with LOH were administrated with same dosage of Andriol Testocaps but lower BMI or weight compared with the westerns. Obviously, drug dosage heavily depends on the weight and BMI. Thus if Chinese patients are given similar dosage of Andriol Testocaps to the western patients, they may face the overdosage of Andriol Testocaps. In this study, we investigate the appropriate dosage of Andriol Testocaps for Chinese patients with LOH.

Interventions

lower dosage of Testosterone Undecanoate Capsule (Andriol) as two groups (40mg and 80mg orally. daily) for 12 weeks and monitored by drug tablet return

Study design

Allocation

Randomised controlled trial

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

Male

Age

30 Years to 70 Years

Healthy volunteers

Inclusion criteria

Inclusion criteria: 1. serum testerone level <350ng/dl 2.decreased sexual desire 3. erection dysfunctiond participants with all the 3 criteria together should be eligible

Exclusion criteria

1.abnormal PSA or prostate cancer 2.hematocrit>45%

Outcome results